What is the clinical evidence from this study?

Population: End-stage cardiomyopathy (n=5). Intervention: Kantrowitz CardioVAD (KCV) vs. Preoperative values. Primary outcome: Cardiac index at 1 month.

What question did this study set out to answer?

The aim is to evaluate the implantation and effectiveness of the Kantrowitz CardioVAD in end-stage cardiomyopathy patients.

July 24, 2026CirculationOpen Access

Circulatory Assistance With a Permanent Implantable IABP: Initial Human Experience

View Full Paper

Ask AI

Bookmark

Key result

Kantrowitz CardioVAD boosts cardiac index ~53% at one month in end-stage cardiomyopathy.

Why the study?

Does the Kantrowitz CardioVAD improve hemodynamics and functional status in patients with end-stage cardiomyopathy?

Key Points

The aim is to evaluate the implantation and effectiveness of the Kantrowitz CardioVAD in end-stage cardiomyopathy patients.
Feasibility trial with 5 men aged 59-73 years
Surgical implantation of the KCV device during cardiopulmonary bypass
Assessment of hemodynamic parameters pre- and post-implantation.
Increased cardiac index from 1.7 to 2.6 L/min/m(2) at 1 month
Decreased creatinine levels from 2.6 to 1.5 mg/dL
Improved NYHA class from IV to II.

Structured PICO

Does the Kantrowitz CardioVAD improve hemodynamics and functional status in patients with end-stage cardiomyopathy?

Population

5 men aged 59 to 73 with end-stage cardiomyopathy refractory to maximal drug treatment, evaluated at 1 month post-implantation.

Intervention

Kantrowitz CardioVAD (KCV) surgically implanted in the descending thoracic aorta on cardiopulmonary bypass.

Comparator

Preoperative baseline values and KCV OFF state.

Outcome

Hemodynamic parameters (cardiac index, creatinine, pulmonary capillary wedge pressure, right atrial pressure) and functional status (NYHA class) at 1 month.surrogate

Main Result

Absolute Event Rate: 2.6% vs 1.7%

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

The initial human experience with the Kantrowitz CardioVAD demonstrates feasibility of implantation and significant hemodynamic and functional improvement in patients with end-stage cardiomyopathy.

Cite This Study

Jeevanandam et al. (2002) studied End-stage cardiomyopathy (n=5). Kantrowitz CardioVAD (KCV) vs. Preoperative values was evaluated on Cardiac index at 1 month. Implantation of the Kantrowitz CardioVAD in 5 men with end-stage cardiomyopathy increased cardiac index from 1.7 to 2.6 L/min/m2 and improved NYHA class from IV to II at 1 month.

synapsesocial.com/papers/6a62d9b3d8aa0f02ee9ceef5 https://doi.org/10.1161/01.cir.0000032899.55215.44

View Full Paper

Ask AI

Bookmark

Implication

The initial human experience with the Kantrowitz CardioVAD demonstrates feasibility of implantation and significant hemodynamic and functional improvement in patients with end-stage cardiomyopathy.

Circulatory Assistance With a Permanent Implantable IABP: Initial Human Experience

Key Points

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Circulatory Assistance With a Permanent Implantable IABP: Initial Human Experience

Key Points

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Also Consider